Cryoport, Inc. reported a total revenue of $47.8 million for the first quarter of 2026, marking a 16.5% increase from $41.0 million in the same period of 2025. The growth was driven by a 17.6% rise in Life Sciences Services revenue, which reached $26.9 million, and a 15.0% increase in Life Sciences Products revenue, totaling $20.9 million. The company's gross margin improved slightly to 45.8% from 45.4% year-over-year, reflecting effective cost management despite rising operational expenses.

The company's net loss for the quarter was $10.5 million, a decrease from a net loss of $12.0 million in the prior year. This improvement was attributed to a significant reduction in losses from discontinued operations, which fell to $1.1 million from $5.2 million. The loss from continuing operations increased to $9.4 million compared to $6.7 million in the previous year, primarily due to higher selling, general, and administrative expenses, which rose by 26.1% to $27.6 million.

In terms of operational metrics, Cryoport supported 766 clinical trials as of March 31, 2026, an increase from 711 trials a year earlier, with 91 of these in Phase 3. The company also reported a strong demand for its BioLogistics Solutions, which generated $21.7 million in revenue, a 16.9% increase year-over-year. The geographic expansion into the EMEA and APAC regions contributed to the growth in Life Sciences Products revenue, which was bolstered by demand from animal health customers.

Strategically, Cryoport completed the divestiture of its CRYOPDP business to DHL for $133 million in June 2025, which has allowed the company to focus on its core temperature-controlled supply chain solutions. The divestiture is expected to enhance Cryoport's capabilities in the EMEA and APAC regions. As of March 31, 2026, the company had cash and cash equivalents of $272.9 million and short-term investments of $130.7 million, providing a solid financial foundation for future growth initiatives. Looking ahead, Cryoport anticipates continued investment in technology and geographic expansion to support its growth in the cell and gene therapy market.

About Cryoport, Inc.

Cryoport Inc. provides global temperature-controlled supply chain solutions for the life sciences industry, specializing in supporting cell and gene therapies, biologics, and high-value biologic materials. Its offerings include logistics, cryopreservation, biostorage, cryogenic systems, and informatics platforms ensuring regulatory compliance, product integrity, and real-time monitoring. The company’s competitive edge lies in its integrated platform, advanced technology, and focus on de-risking critical biological material transportation and storage.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.